The gross margin trajectory indicates strong product economics and manufacturing efficiencies as volumes scale, but the operating margin of -24.1% in 2026Q2, as reported, reveals that commercial and R&D investments are still outpacing revenue. The gap between gross and operating margins is widening, implying that the company is reinvesting heavily in growth, which may be appropriate for a commercial-stage biotech but pressures near-term profitability. Investors should monitor whether operating leverage can eventually translate gross margin gains into positive operating income, especially given the elevated SBC expense.

The negative ROIC across all quarters, with a low of -16.4% in 2026Q1, suggests that Mirum is in a heavy investment phase, deploying capital into R&D and commercial infrastructure ahead of revenue scale. The asset-light model, with minimal PPE, means returns are driven by intangible assets and working capital, but the current negative returns are typical for a biotech scaling up. The improvement from -16.4% to -9.7% in the latest quarter may indicate early signs of efficiency, but sustained positive ROIC is likely several years away.

The dramatic reduction in CCC is primarily due to DPO rising from 60 to 124 days, which suggests Mirum is leveraging its supplier relationships to preserve cash, a common strategy for cash-burning companies. DSO has remained stable around 70 days, indicating consistent collection practices, while DIO has declined from 112 to 77 days, possibly reflecting better inventory management. However, the negative FCF margin of -155.3% in 2026Q2 indicates that despite working capital improvements, the company is still burning cash heavily, and the reliance on extended payables may not be sustainable long-term.

The negative equity position, combined with rising debt, suggests that Mirum is funding its growth through borrowings, which raises financial risk. Interest coverage is negative at -6.99 in 2026Q2, meaning operating income is insufficient to cover interest expenses, a concern for debt sustainability. The company's cash balance of $330.7M provides a near-term cushion, but the rapid debt accumulation and negative equity warrant close monitoring of refinancing risk and covenant compliance.

The current and quick ratios are healthy, suggesting that Mirum can meet its near-term obligations even as it burns cash. However, the negative FCF margin of -155.3% in 2026Q2 implies that the cash balance could deplete quickly if the burn rate persists. The company's ability to raise additional capital, either through debt or equity, will be critical to maintaining liquidity, but the negative equity position may limit future borrowing capacity.